- Type / Class
- Equity / COM
- Shares outstanding
- 258,506,508
- Total 13F shares
- 151,305,375
- Share change
- +43,445,139
- Total reported value
- $559,771,279
- Put/Call ratio
- 23%
- Price per share
- $3.70
- Number of holders
- 200
- Value change
- +$165,257,335
- Number of buys
- 124
- Number of sells
- 62
Quarterly Holders Quick Answers
What is CUSIP 29664W105?
CUSIP 29664W105 identifies ESPR - Esperion Therapeutics, Inc. - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29664W105:
Top shareholders of ESPR - Esperion Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
5.7%
|
14,833,791
|
$39,309,546 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.7%
|
12,092,449
|
$32,044,990 | — | 30 Sep 2025 | |
| Two Seas Capital LP |
13F
13D/G
|
Company |
4.7%
from 13D/G
|
9,749,724
|
$25,836,769 | — | 30 Sep 2025 | |
| WASATCH ADVISORS LP |
13F
|
Company |
2.7%
|
7,061,857
|
$18,713,921 | — | 30 Sep 2025 | |
| PenderFund Capital Management Ltd. |
13F
|
Company |
2.6%
|
6,676,519
|
$17,692,775 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
4,751,396
|
$12,593,578 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
4,478,834
|
$11,868,910 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.6%
|
4,055,626
|
$10,747,409 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
1.4%
|
3,711,069
|
$9,834,333 | — | 30 Sep 2025 | |
| BB BIOTECH AG |
13D/G
|
— |
4.9%
|
9,694,064
|
$8,821,598 | -$227,500 | 04 Mar 2025 | |
| AIGH Capital Management LLC |
13F
|
Company |
1.2%
|
3,000,000
|
$7,950,000 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.98%
|
2,521,439
|
$6,681,814 | — | 30 Sep 2025 | |
| ROYCE & ASSOCIATES LP |
13F
|
Company |
0.89%
|
2,293,488
|
$6,077,743 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.87%
|
2,238,618
|
$5,932,338 | — | 30 Sep 2025 | |
| BIOTECH TARGET N V |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,477,964
|
$5,575,065 | — | 24 May 2021 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.76%
|
1,953,058
|
$5,175,604 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.74%
|
1,908,000
|
$5,056,200 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.72%
|
1,848,437
|
$4,898,358 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.66%
|
1,708,807
|
$4,528,339 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.59%
|
1,530,364
|
$4,055,465 | — | 30 Sep 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.58%
|
1,500,000
|
$3,975,000 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.48%
|
1,246,310
|
$3,302,722 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.38%
|
974,856
|
$2,583,368 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.37%
|
954,449
|
$2,529,290 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.37%
|
945,491
|
$2,505,552 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.35%
|
909,232
|
$2,410,000 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.3%
|
773,900
|
$2,050,835 | — | 30 Sep 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.29%
|
750,000
|
$1,987,500 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.26%
|
681,294
|
$1,805,429 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.24%
|
619,767
|
$1,642,383 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.23%
|
586,424
|
$1,554,024 | — | 30 Sep 2025 | |
| John B. Harlow Jr. |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
804,536
mixed-class rows
|
$1,316,061 | — | 04 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.18%
|
463,088
|
$1,227,183 | — | 30 Sep 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.17%
|
426,866
|
$1,131,195 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.15%
|
382,087
|
$1,012,531 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.14%
|
357,358
|
$946,999 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.13%
|
335,609
|
$889,363 | — | 30 Sep 2025 | |
| Summit Wealth Group, LLC |
13F
|
Company |
0.12%
|
323,000
|
$855,950 | — | 30 Sep 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.12%
|
319,191
|
$845,856 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.12%
|
304,572
|
$807,115 | — | 30 Sep 2025 | |
| Mariner, LLC |
13F
|
Company |
0.12%
|
302,514
|
$801,662 | — | 30 Sep 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.11%
|
296,811
|
$786,549 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.11%
|
284,906
|
$755,001 | — | 30 Sep 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.11%
|
277,491
|
$735,343 | — | 30 Sep 2025 | |
| MACKENZIE FINANCIAL CORP |
13F
|
Company |
0.11%
|
272,958
|
$723,339 | — | 30 Sep 2025 | |
| Joanne M. Foody |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
472,862
mixed-class rows
|
$709,168 | — | 17 Jul 2024 | |
| Brevan Howard Capital Management LP |
13F
|
Company |
0.1%
|
263,276
|
$697,681 | — | 30 Sep 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.1%
|
254,265
|
$673,802 | — | 30 Sep 2025 | |
| Diametric Capital, LP |
13F
|
Company |
0.09%
|
236,145
|
$625,784 | — | 30 Sep 2025 | |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP |
13F
|
Company |
0.09%
|
222,482
|
$589,577 | — | 30 Sep 2025 |
Institutional Holders of Esperion Therapeutics, Inc. - COM (ESPR) as of Q4 2025
As of 31 Dec 2025,
Esperion Therapeutics, Inc. - COM (ESPR) was held by
200 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
151,305,375 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Two Seas Capital LP, WASATCH ADVISORS LP, D. E. Shaw & Co., Inc., ORBIMED ADVISORS LLC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MARSHALL WACE, LLP, and TWO SIGMA INVESTMENTS, LP.
This page lists
200
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
187
Q4 2025 holders
200
Holder diff
13
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.